Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
OTC Markets OTCQB - Delayed Quote USD

Evofem Biosciences, Inc. (EVFM)

Compare
0.0080
-0.0004
(-4.76%)
At close: February 27 at 3:00:00 PM EST

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Ms. Saundra Pelletier Interim Chair, President & CEO 1.52M -- 1970
Ms. Ivy Zhang CPA CFO & Secretary 438.85k -- 1978
Ms. Ellen Thomas Chief of Staff -- -- --
Ms. Amy Raskopf Chief Business Development Officer -- -- --
Ms. Kathy Gallo-Doyle Senior Vice President of Commercial Operations -- -- --

Evofem Biosciences, Inc.

7770 Regents Roas
Suite 113-618
San Diego, CA 92122
United States
858 550 1900 https://www.evofem.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
37

Description

Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.

Corporate Governance

Evofem Biosciences, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

March 25, 2025 at 12:30 PM UTC - March 31, 2025 at 12:30 PM UTC

Evofem Biosciences, Inc. Earnings Date

Recent Events

January 10, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

December 23, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

November 25, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

November 14, 2024 at 12:00 AM UTC

10-Q: Periodic Financial Reports

November 6, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

October 31, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

October 28, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

October 3, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

September 25, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

September 23, 2024 at 12:00 AM UTC

PRE 14A: Proxy Statements

Related Tickers

Waiting for permission
Allow microphone access to enable voice search

Try again.